Abstract

Centene will report its second-quarter results on July 28, 2026 Pre-MKt; this preview summarizes street estimates for revenue, margins, net income, and adjusted EPS, compares them with the prior quarter, and highlights business mix and segment drivers shaping expectations.

Market Forecast

Consensus modeling points to second-quarter revenue of 47.62 billion US dollars, implying 7.44% year-over-year growth; the quarter’s estimated EBIT is 563.83 million US dollars with 69.19% year-over-year growth, and adjusted EPS is forecast at 1.09 with 26.52% year-over-year growth. Management’s margin trajectory embedded in estimates implies steady gross profit margin trends and a modest improvement in net profitability versus last year, though explicit company guidance on quarterly gross margin and net margin was not provided in the prior release.

Centene’s core insurance and services business remains the principal revenue engine, with the segment’s outlook tied to Medicaid redetermination dynamics, Medicare Advantage medical cost trends, and marketplace pricing actions. The segment with the most promising growth is the insurance and services unit, supported by pricing resets and membership normalization; the last quarter’s revenue base for this unit was 44.66 billion US dollars, positioning it for mid-single to high-single-digit growth year over year.

Last Quarter Review

In the first quarter, Centene reported revenue of 49.94 billion US dollars, a gross profit margin of 15.00%, GAAP net income attributable to shareholders of 1.54 billion US dollars, a net profit margin of 3.42%, and adjusted EPS of 3.37, up 16.21% year over year.

A key highlight was strong operating leverage that helped deliver notable EPS outperformance versus consensus, supported by favorable utilization trends. The main business mix remained concentrated in insurance and services, which generated 44.66 billion US dollars of revenue, while premium tax represented 5.29 billion US dollars.

Current Quarter Outlook

Main insurance and services franchise

The core franchise consists of government-sponsored health plans across Medicaid, Medicare Advantage, and marketplace offerings. For the current quarter, market models indicate revenue normalization from the prior quarter’s seasonal peak, but continued year-over-year expansion of 7.44% anchored by rate actions and a stabilized membership base. Medical cost ratio control is the central variable: moderation in acute utilization and pharmacy trend management should underpin the estimated EPS growth of 26.52% year over year. In addition, continuing administrative efficiency and technology-enabled care management are expected to support an EBIT mix that skews toward recurring plan operations.

Most promising growth vector

Insurance and services is positioned as the largest and most scalable growth vector, given its breadth across Medicaid and exchange markets. With a last-quarter revenue base of 44.66 billion US dollars, incremental pricing discipline and risk adjustment calibration could translate into better earnings conversion even on mid-single-digit top-line growth. Membership shifts driven by Medicaid redeterminations are cycling, which reduces churn pressure and improves visibility on acuity and care gap closure. If pharmacy benefit dynamics remain stable, the EBIT estimate of 563.83 million US dollars and the EPS estimate of 1.09 appear achievable, with upside tied to lower-than-assumed non-inpatient utilization.

Key stock-price swing factors this quarter

- Medical cost trends and utilization: Any deviation in inpatient admissions, outpatient surgeries, or high-cost specialty drugs relative to plan expectations would move the medical loss ratio and drive variance in EBIT versus the 563.83 million US dollars estimate. A benign flu/COVID backdrop relative to last year would be supportive. - Medicaid redetermination cadence: Stabilization of eligibility recertifications could temper membership volatility and claims seasonality, which would help margin predictability and reduce reserve noise. - Marketplace pricing and risk adjustment: Updated pricing for the 2026 plan year, retention in higher-margin geographies, and accuracy of risk adjustment submissions are likely to influence the sustainability of the 26.52% year-over-year EPS growth projection and sentiment into the back half.

Analyst Opinions

Bullish views dominate recent commentary, with the majority of institutions pointing to improving utilization and predictable membership trends as supports for year-over-year earnings growth this quarter. Analysts highlight the estimated 7.44% revenue growth, the projected 69.19% EBIT expansion, and disciplined pricing as key positives that could sustain margin improvement. Several well-followed sell-side teams emphasize that operational efficiency and pharmacy cost management create an asymmetry to the upside if utilization remains contained through the summer months.